The most common adverse reaction to zoledronic acid (ZOL) infusion is the acutephase reaction (APR), characterized by transient, usually mild, flu-like symptoms. Previous treatment with oral aminobisphosphonates (BPs) was reported as an independent protective factor for APR, and an association between APR and 25-hydroxyvitamin D (25[OH]D) levels in BP-naïve patients treated with ZOL was identified. The aim of our study was to confirm this association and to see if the association was different in patients previously treated with oral BPs compared with BP-naïve patients, and to investigate the role of 25(OH)D for the time of APR onset.

Acute phase reactions after zoledronic acid infusion: protective role of 25-OH vitamin D and previous oral bisphosphonate therapy / C. Crotti, N.B. Watts, M. De Santis, A. Ceribelli, G. Fabbriciani, F. Cavaciocchi, B. Marasini, C. Selmi, M. Massarotti. - In: ENDOCRINE PRACTICE. - ISSN 1530-891X. - (2018). [Epub ahead of print] [10.4158/EP161638.OR]

Acute phase reactions after zoledronic acid infusion: protective role of 25-OH vitamin D and previous oral bisphosphonate therapy

C. Crotti;C. Selmi;
2018

Abstract

The most common adverse reaction to zoledronic acid (ZOL) infusion is the acutephase reaction (APR), characterized by transient, usually mild, flu-like symptoms. Previous treatment with oral aminobisphosphonates (BPs) was reported as an independent protective factor for APR, and an association between APR and 25-hydroxyvitamin D (25[OH]D) levels in BP-naïve patients treated with ZOL was identified. The aim of our study was to confirm this association and to see if the association was different in patients previously treated with oral BPs compared with BP-naïve patients, and to investigate the role of 25(OH)D for the time of APR onset.
osteoporosis; zoledronic acid; 25 OH vitamin D; acute phase reaction
Settore MED/16 - Reumatologia
2018
2-mar-2018
Article (author)
File in questo prodotto:
File Dimensione Formato  
ep161638.or.pdf

accesso riservato

Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 206.73 kB
Formato Adobe PDF
206.73 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/565959
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 21
  • ???jsp.display-item.citation.isi??? 13
social impact